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Introduction
CD8+ T cells are immune cells that play a central role in the defense against viral infection, intracellular 
pathogens, and malignant tumors. The thymus produces T cells, including CD8+ T cells. Thymic production 
of  functionally competent CD8+ T cells is dependent on the TCR-mediated positive selection of  immature 
thymocytes with a set of  major histocompatibility complex (MHC) class I–associated self-peptides that are 
presented by cortical thymic epithelial cells (cTECs). The MHC class I–associated self-peptides displayed 
by cTECs are produced by the thymoproteasome, a form of  proteasome specifically expressed in cTECs, 
because its unique catalytic subunit β5t, encoded by Psmb11, is exclusively and abundantly transcribed in 
cTECs (1–3). β5t deficiency in mice leads to the aberrant positive selection of  CD8+ T cells, which are 
reduced in cellularity and are defective in TCR-mediated immune responses (4–6). β5t in humans is encod-
ed by PSMB11 in chromosome 14 and is also detectable specifically in cTECs (7, 8). However, the function 
of  β5t-containing thymoproteasome in humans is unknown.
The present study describes a human genomic variation of  PSMB11 single nucleotide polymorphism, 
rs34457782, of  which its minor allele variation, guanine (G) to adenine (A), is detectable at an appreciable 
The Psmb11-encoded β5t subunit of the thymoproteasome, which is specifically expressed 
in cortical thymic epithelial cells (cTECs), is essential for the optimal positive selection of 
functionally competent CD8+ T cells in mice. Here, we report that a human genomic PSMB11 
variation, which is detectable at an appreciable allele frequency in human populations, alters 
the β5t amino acid sequence that affects the processing of catalytically active β5t proteins. 
The introduction of this variation in the mouse genome revealed that the heterozygotes 
showed reduced β5t expression in cTECs and the homozygotes further exhibited reduction in 
the cellularity of CD8+ T cells. No severe health problems were noticed in many heterozygous 
and 5 homozygous human individuals. Long-term analysis of health status, particularly in the 
homozygotes, is expected to improve our understanding of the role of the thymoproteasome-
dependent positive selection of CD8+ T cells in humans.
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allele frequency in humans. This minor allele variation alters 
the amino acid sequence of  human β5t at the 49th amino acid, 
glycine (Gly), to serine (Ser), which affects the processing of  
nascent propeptides to catalytically active β5t proteins. The 
introduction of  this G-to-A variation in the mouse genome 
by homologous recombination in embryonic stem cells (ES 
cells) revealed that the heterozygous mice showed reduced 
β5t expression in cTECs and the homozygous mice exhibited 
further reduced cellularity of  CD8+ T cells in vivo, suggesting 
that the production of  CD8+ T cells is affected in heterozy-
gous and/or homozygous humans. A cohort study identified 
many heterozygotes and 5 individuals who are homozygous 
in this variation. So far, we know of  no clear associations 
with severe health problems in those heterozygotes or homo-
zygotes, at least indicating that this genomic variation does 
not cause apparently severe defects, including lethality, in 
humans. Long-term analysis of  immune cells and health sta-
tus in those heterozygotes and homozygotes, particularly in 
the homozygotes, is expected to improve our understanding 
of  the role of  thymoproteasome-dependent positive selection 
of  CD8+ T cells in humans.
Results
Single nucleotide variant rs34457782 in human populations. We 
previously showed that β5t-containing thymoproteasome is 
specifically expressed in cTECs in mice and humans (2, 7, 
9) and is essential for the optimal positive selection of  func-
tionally competent CD8+ T cells in mice (2, 4, 6). In order to 
explore the function of  β5t in humans, we surveyed the NCBI 
public database for variations in the human PSMB11 genome 
sequence and found a number of  PSMB11 single nucleotide 
variants that potentially affect the amino acid sequence of  
human β5t protein (Supplemental Table 1; supplemental mate-
rial available online with this article; https://doi.org/10.1172/
jci.insight.93664DS1). Among those variants, we noticed that the most common variant, rs34457782, carries 
a minor allele variation (G to A) that changes the 49th amino acid of  β5t protein from Gly to Ser (G49S) at 
an appreciable allele frequency in human populations (Supplemental Table 2). The minor allele frequency 
appears to vary among human populations; it is 4.85% in Han Chinese in Beijing, 3.03% in Finnish in Fin-
land and Kinh Vietnamese in Ho Chi Minh, and 0.00% in African Caribbeans in Barbados, Americans of  
African Ancestry in Southwestern US, and several other populations (Supplemental Table 2). In our own 
surveys of  human genome samples previously collected at the University of  Tokushima (10, 11), the minor 
allele frequency was 3.11% in 949 local healthy Japanese volunteers (Supplemental Table 3), whereas in the 
NCBI public database, the frequency was 2.40% in 104 Japanese people in Tokyo (Supplemental Table 2; 
Fisher’s exact test indicated no significant differences in minor allele frequencies detected in Tokushima and 
Tokyo). These results indicate that the rs34457782 variant, which affects the amino acid sequence of  β5t 
protein, is present at appreciable frequencies in various human populations.
G49S variation affects processing of  human β5t protein. The rs34457782 variant alters the 49th amino acid 
Gly (G49) of  β5t protein, which is a highly conserved amino acid among vertebrate species, along with 
neighboring amino acids (Table 1). Mature β5t protein possesses a triple threonine amino terminus that 
is responsible for the proteolytic activity of  catalytic β subunits and is generated by the cleavage of  the 
propeptide (12). G49 is located at the carboxyl terminus of  the propeptide to be cleaved off  for the gener-
ation of  catalytically active β5t protein (Table 1). Previous studies on other β subunits suggested that the 
alteration of  this Gly residue might affect the propeptide cleavage (13–15). In order to examine whether the 
G49S variation might actually affect the processing of  β5t protein, human embryonic kidney 293T cells were 
Table 1. β5t amino acid sequences in different species in accordance 
with NCBI database
Species Amino acid sequence
Homo sapiens RLAHGTTTLAFRFRHG 
Pan troglodytes (Chimpanzee) RLAHGTTTLAFRFRHG 
Pongo pygmaeus (Orangutan) RLAHGTTTLAFRFRHG 
Callithrix jacchus (Marmoset) RLAHGTTTLAFRFRHG 
Tarsius syrichta (Tarsier) KLAHGTTTLAFRFRHG 
Loxodonta africana (Elephant) KLAHGTTTLAFRFCHG 
Bos taurus (Cow) RLAHGTTTLAFRFRHG 
Equus caballus (Horse) RLAHGTTTLAFRFRHG 
Sus scrofa (Pig) RLAHGTTTLAFRFRDG 
Oryctolagus cuniculus (Rabbit) QLAHGTTTLAFRFRHG 
Canis familiaris (Dog) RLAHGTTTLAFRFRHG 
Rattus norvegicus (Rat) RLAHGTTTLAFRFRHG 
Mus musculus (Mouse) RLAHGTTTLAFRFRHG 
Macropus eugenii (Wallaby) ELAHGTTTLAFRFRHG 
Monodelphis domestica (Opossum) DLAHGTTTLAFRFQHG 
Pteropus vampyrus (Bat) RLAHGTTTLAFRFRHG 
Tursiops truncatus (Dolphin) RLAHGTTTLAFRFRHG 
Ornithorthynchus anatinus (Platypus) DLAHGTTTLAFRFRHG 
Anolis carolinessis (Anole lizard) -LSHGTTTLAFRCSHG
Xenopus tropicalis (African clawed toad) ---HGTTTLAFIYSGG
Oryzias latipes (Medaka fish) ---HGTTTLAFVFQGG
Takifugu rubripes (Fugu fish) PLSHGTTTLAFIFQGG 
Danio rerio (Zebrafish) TLSHGTTTLGFAFQGG 
Gasterosteus aculeatus (Stickleback fish) PMSHGTTTLAFLFQGG 
Sequences corresponding to human amino acid positions 45–60 are shown. Glycine 
at position 49 is conserved in all species and shown in bold. Other conserved amino 
acids are shown in italics. Human and mouse are shown in bold.
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transfected with a plasmid that was engineered to express FLAG-tagged human β5t 
protein of  either WT or G49S variant sequence (Figure 1A). For the formation of  func-
tionally active proteasomes, the ordered incorporation of  β subunits onto the assem-
bled α-ring is followed by the cleavage of  β subunit propeptides (12). The immunoblot 
analysis of  FLAG-tagged β5t proteins in total cell lysates showed that both nascent 
precursor protein and processed mature β5t protein were detected when the cells were 
transfected with WT β5t–expressing plasmid (Figure 1A). However, parallel analysis 
of  β5t-G49S–expressing cells revealed that the mature β5t protein was less abundant 
than the nascent precursor proteins (Figure 1A). In β5t-G49S–expressing cells, we also 
detected an additional FLAG signal with an intermediate molecular size (denoted by 
an asterisk, Figure 1A), possibly representing aberrantly processed abnormal β5t pro-
tein. Immunoblot analysis of  proteins immunoprecipitated with anti-α6 antibody from 
the 26S proteasome fraction separated by glycerol gradient centrifugation revealed that 
the majority of  β5t proteins incorporated in fully assembled proteasome complex in 
WT β5t–expressing cells were mature β5t protein rather than nascent precursor protein, 
whereas an appreciable fraction of  β5t was the precursor protein in β5t-G49S–expressing cells (Figure 1B). 
An additional signal with an intermediate molecular size was also detectable (Figure 1B). These results 
indicate that human β5t protein with the G49S variation is inefficient in the processing of  the propeptide 
to generate a mature β5t subunit that exposes the catalytically 
active triple threonine amino terminus. Unlike WT β5t protein, 
β5t-G49S protein in a fully assembled proteasome complex 
either remains unprocessed or undergoes abnormal processing.
Generation of  β5t-G49S–knock-in mice. The inefficient pro-
cessing of  human β5t-G49S protein in cells prompted us to 
wonder whether humans carrying the G49S variants might 
have a problem in the processing of  β5t protein in their cTECs 
and further have consequences in the generation of  CD8+ T 
cells. In order to begin addressing the effects of  G49S variation 
in vivo, we next aimed to generate knock-in mice that carried 
the genome sequence corresponding to rs34457782, which 
encoded β5t-G49S protein in mice.
We decided that the introduction of  the G49S variation in 
the mouse genome was a reasonable approach to explore the 
effect of  this variation in humans in vivo because (i) the 49th 
amino acid, Gly, was highly conserved among vertebrate spe-
cies, including humans and mice (Table 1), as well as among 
many mouse strains (Table 2), and (ii) the processing of  mouse 
β5t-G49S protein expressed in mouse embryonic fibroblasts 
(MEFs) was inefficient and aberrant, similarly to the processing 
of  human β5t-G49S protein (Figure 1C).
To generate knock-in mice that carried the genome sequence 
corresponding to rs34457782, a targeting vector was introduced 
into mouse ES cells for homologous recombination, and the ES 
Figure 1. G49S variation affects processing of human and mouse β5t protein. (A) WT (hβ5t 
WT-Flag) and G49S (hβ5t G49S-Flag) human β5t tagged at C-terminus with the Flag epitope 
was transfected into HEK293T cells. Proteins extracted from transfected cells were immu-
noblotted with anti-Flag, anti-α6, and anti-β7 antibodies. (B) Proteins extracted from hβ5t 
WT-Flag and hβ5t G49S-Flag transfected cells were fractionated by glycerol gradient centrifuga-
tion, and the fractions containing the 26S proteasome were immunoprecipitated with anti-α6 
antibody followed by immunoblotting with anti-Flag, anti-α6, and anti-β7 antibodies. (C) WT or 
G49S mouse β5t (mβ5t) tagged with the Flag epitope at either N-terminus or C-terminus was 
transduced in fibroblasts isolated from β5i-deficient embryos. Cells were treated with IFN-γ 
to induce the expression of β1i and β2i, and extracted proteins were immunoprecipitated and 
immunoblotted with anti-Flag antibody. See complete unedited blots in the supplemental 
material. Asterisks indicate additional signals with an intermediate molecular size.
Table 2. β5t amino acid sequences at 
positions 45–60 in different mouse 
strains obtained from the Ensemble 
database
Mouse strain Amino acid sequence
129S1/SvImJ RLAHGTTTLAFRFRHG
BALB/cJ RLAHGTTTLAFRFRHG
C57BL/6 RLAHGTTTLAFRFRHG
CBA/J RLAHGTTTLAFRFRHG
DBA2/J RLAHGTTTLAFRFRHG
C3H/HeJ RLAHGTTTLAFRFRHG
CAST/EiJ RLAHGTTTLAFRFRHG
FVB/NJ RLAHGTTTLAFRFRHG
LP/J RLAHGTTTLAFRFRHG
NOD/ShLtJ RLAHGTTTLAFRFRHG
NZO/HlLtJ RLAHGTTTLAFRFRHG
PWK/PhJ RLAHGTTTLAFRFRHG
SPRET/EiJ RLAHGTTTLAFRFRHG
WSB/EiJ RLAHGTTTLAFRFRHG
Glycine at position 49 is conserved in all 
strains and shown in bold letters. Other 
conserved amino acids are highlighted in 
italicized letters.
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cells were positively and negatively selected for the incorporation of the targeted allele (Figure 2A). The ES cells 
were screened by PCR analysis (Figure 2B), confirmed by Southern blot analysis (Figure 2C), and verified by 
sequence analysis (Figure 2D). Three founder mice were mated with CAG-Cre–transgenic mice for germline 
removal of the loxP-Neo-loxP cassette (Figure 2A). All of the 3 mouse strains generated in this study exhibited 
essentially identical phenotypes; here, we describe the following results from one strain of knock-in mice.
G49S variation in mice diminishes β5t expression in cTECs. β5t-G49S–knock-in mice, both heterozygotes 
and homozygotes, were born and grew to be fertile without apparent problems. Biochemical analysis of  β5t-
G49S–expressing cells indicated that the human and mouse β5t-G49S proteins were inefficient and aberrant 
in the processing to generate mature β5t protein (Figure 1), suggesting that in β5t-G49S–knock-in mice, the 
processing of  mature β5t protein in cTECs might be inefficient and aberrant, which could in turn affect 
the production of  CD8+ T cells. Consequently, we examined the thymic architecture in β5t-G49S–knock-in 
mice, focusing on the expression of  β5t proteins in cTECs.
H&E staining of  the thymic sections showed that the corticomedullary architecture of  the thymus 
was generated in heterozygous and homozygous β5t-G49S–knock-in mice, without noticeable abnor-
malities (Figure 3A). Flow cytometric analysis of  liberase-digested thymic cells indicated that the num-
bers of  thymic cells, including cTECs and medullary TECs (mTECs), were normal in heterozygous and 
homozygous β5t-G49S–knock-in mice (Figure 3B). Immunofluorescence analysis of  the thymic sections 
revealed the expression of  β5t proteins in the cortex and of  Aire proteins in the medulla in heterozy-
gous and homozygous β5t-G49S–knock-in mice (Figure 3C). However, the expression of  β5t proteins 
in cTECs was significantly reduced in heterozygous (P < 0.05) and more severely in homozygous (P < 
0.01) β5t-G49S–knock-in mice (Figure 3D), indicating that G49S variation affects the expression of  β5t 
proteins for the optimal expression of  β5t-containing thymoproteasomes in cTECs in vivo. In contrast, 
the amounts of  MHC class I and class II molecules expressed in cTECs and mTECs were not altered in 
heterozygous and homozygous β5t-G49S–knock-in mice (Figure 3, E and F). These results indicate that 
Figure 2. Generation of β5t-G49S–knock-in mice. (A) Schematic diagram of β5t genomic locus in mouse chromosome 14. The diagrams for targeting 
vector and targeted allele are also shown. Targeted mice were further crossed with CAG-Cre–transgenic mice to delete the PGK-Neo insertion. Arrow-
heads indicate the primers for genomic PCR. Probe for Southern blot analysis is also shown. DT-A, diphtheria toxin A; PGK-Neo, phosphoglycerate kinase 
I promoter–driven neomycin resistance gene. (B) Gel electrophoresis of PCR-amplified genomic DNA. Positions for primers are shown in A. Plasmid DNA 
containing the targeted fragment was used as positive control. (C) Southern blot analysis of XbaI-digested genomic DNA from targeted ES cells and con-
trol TT2 ES cells. Probe is shown in A. (D) The G-to-A 1 bp substitution at amino acid position 49 (Gly to Ser) of β5t in genomic DNA isolated from mouse 
tails in WT, heterozygous (hetero), and homozygous (homo) knock-in mice. See complete unedited blots in the supplemental material. Asterisks indicate 
nucleotides where 1-bp substitution is introduced.
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G49S variation in mice decreases β5t expression in cTECs in heterozygotes and homozygotes, and the 
decrease is greater in the latter.
β5t-G49S variation in mice impairs CD8+ T cell production in thymus. The reduced expression of  β5t proteins 
in cTECs suggested the possibility that the production of  CD8+ T cells in the thymus might be affected in 
β5t-G49S–knock-in mice. To examine this possibility, we performed flow cytometric analysis of  thymocytes 
from β5t-G49S–knock-in mice. The analysis of  CD4, CD8, and TCRβ expression profiles indicated that the 
frequencies and numbers of  CD4–CD8–, CD4+CD8+ (double positive, DP), and CD4+CD8– TCRβhi thymo-
cytes were unaltered in heterozygous and homozygous β5t-G49S–knock-in mice (Figure 4A). However, the 
cellularity of  CD4–CD8+ TCRβhi thymocytes was significantly (P < 0.05) reduced in homozygous, but not 
heterozygous, β5t-G49S–knock-in mice (Figure 4A). Within DP thymocytes, the TCRβhiCD5intermediate DP3 
population, which is enriched with DP thymocytes that are destined to become CD4–CD8+ TCRβhi thymo-
cytes (16), and which is likely enriched with the postselection CD8-lineage “stage 5” DP thymocytes (17), 
was specifically reduced in cellularity (Figure 4B). These results indicate that the production of  CD4–CD8+ 
TCRβhi thymocytes is specifically reduced in homozygous, but not heterozygous, β5t-G49S–knock-in mice.
Consequently, the cellularity of  CD4–CD8+ TCRβhi T cells, but not CD4+CD8– TCRβhi T cells in the 
periphery, including the spleen, was reduced in homozygous, but not heterozygous, β5t-G49S–knock-in 
mice (Figure 4C). The reduction in cellularity of  CD8+ T cells was associated with the reduced number 
Figure 3. G49S variation in mice diminishes β5t expression in cTECs. (A) H&E staining of thymic sections from indicated mice at 5 weeks old. Rep-
resentative data from 3 independent experiments are shown. Scale bars: 1 mm. (B) Flow cytometric analysis of enzyme-digested thymic cells isolated 
from 2-week-old mice of indicated genotypes. Dot plots show CD326 (EpCAM) and CD45 expression in total thymic cells (left), and UEA-1 reactivity 
and CD249 expression in propidium iodide– (PI–) CD45–CD326+ viable thymic epithelial cells (middle). Graphs show cell number (means ± SEM, n = 4) 
of PI–CD45–CD326+UEA1–CD249+ cTECs and PI–CD45–CD326+UEA1+CD249– mTECs. (C) Immunofluorescence analysis of β5t (green), Aire (red), and UEA-1 
binding molecules (blue) in thymic sections from 5-week-old mice of indicated genotypes. Representative data from 3 independent experiments are 
shown. Scale bars: 75 μm. (D–F) Histograms show the expression of β5t (D), MHC class I (E), and MHC class II (F) in cTECs and mTECs of WT (black 
lines), heterozygous (blue lines), and homozygous (red lines) knock-in mice at 2 weeks old. Graphs show relative fluorescence intensity (RFI, n = 3) of 
β5t (D), MHC class I (E), and MHC class II (F) expression normalized to the mean fluorescence intensity measured in WT cells. *P < 0.05, **P < 0.01 by 
one-way ANOVA with Tukey’s correction.
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of  CD44loCD122lo naive CD8+ T cells (Figure 4D), similar to β5t-deficient mice (6), in agreement with 
the reduction in the thymic production of  CD8+ T cells. Nevertheless, the numbers of  CD8+ T cells in 
the thymus and the spleen of  homozygous β5t-G49S–knock-in mice were reduced to approximately 
40% of  those in control mice (Figure 4, A and C), and the reduction was less severe than that in β5t-de-
ficient mice (Figure 5). These results indicate that the production of  CD8+ T cells is reduced in homo-
zygous, but not heterozygous, β5t-G49S–knock-in mice, and the reduction in CD8+ T cell production is 
not as severe as that in β5t-deficient mice.
β5t-G49S variation in association studies in human populations. The results described so far indicat-
ed that the β5t-G49S variation caused the reduction in β5t expression and in CD8+ T cell produc-
tion in mice, which prompted us to address whether β5t-G49S variation in humans might actually 
affect CD8+ T cell production and, more importantly, human health. As CD8+ T cells are important for 
immune responses toward infectious diseases, including viral infection, we next examined whether the 
rs34457782 variation might be associated with the susceptibility to hepatitis B, hepatitis C, and tuber-
culosis in human populations. We compared the minor allele frequency of  the rs34457782 variation 
among Japanese healthy volunteers (417 samples), Japanese patients with hepatitis B (521 samples) and 
Figure 4. β5t-G49S variation in mice impairs CD8+ T cell production in thymus. (A) Flow cytometric analysis of thymocytes from 5-week-old mice of 
indicated genotypes. Shown are dot plots of CD4 and CD8 expression (left), TCRβ expression (middle) in PI– viable cells, and dot plots of CD4 and CD8 
expression in PI–TCRβhi cells (right). Graphs show the number (means ± SEM, n = 4) of indicated thymocyte populations. (B) Flow cytometric analysis 
of thymocytes from 5-week-old mice of indicated genotypes. Shown are dot plots of TCRβ and CD5 expression in CD4+CD8+ thymocytes. Boxes 
indicate TCRβloCD5lo (DP1), TCRβintermediateCD5hi (DP2), and TCRβhiCD5intermediate (DP3) CD4+CD8+ thymocytes. Graphs show the frequency (means ± SEM, n 
= 4) of indicated thymocyte populations. (C) Flow cytometric analysis of splenocytes from 5-week-old mice of indicated genotypes. Histograms show 
TCRβ expression in PI– viable cells, and dot plots show CD4 and CD8 expression in PI–TCRβhi viable T cells. Graphs show the number (means ± SEM, n 
= 4) of CD4+CD8– TCRβhi T cells and CD4–CD8+ TCRβhi T cells. (D) Flow cytometric analysis of splenocytes from 5-week-old mice of indicated genotypes. 
Shown are dot plots of CD44 and CD122 expression in CD4–CD8+ TCRβhi and CD4+CD8– TCRβhi T cells. Graphs show the number (means ± SEM, n = 4) 
of indicated splenocyte populations. Numbers in dot plots and histograms indicate frequency of cells within indicated area. *P < 0.05, **P < 0.01 by 
one-way ANOVA with Tukey’s correction.
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hepatitis C (2,537 samples), and Japanese individuals who underwent spontaneous clearance of  hep-
atitis C virus (785 samples) (18, 19). We also compared the minor allele frequency of  the rs34457782 
variation between Indonesian healthy controls (514 samples) and Indonesian patients with pulmonary 
tuberculosis (573 samples) (20). We detected no association with this variation in any of  those infec-
tious diseases (Table 3 and Table 4), indicating that the minor allele of  the rs34457782 variation is not 
associated with the susceptibility to infection with hepatitis B virus, hepatitis C virus, and Mycobacte-
rium tuberculosis. These results suggest that humans who are heterozygous in the β5t-G49S variant are 
not defective in the immune responses to these infectious pathogens, in agreement with the results of  
the analysis of  heterozygous β5t-G49S–knock-in mice showing that the heterozygotes are not impaired 
in the production of  normal cellularity of  CD8+ T cells.
It should also be noted that the analysis described in Table 3 included 2 homozygotes in 4,260 Japanese 
people, indicating that the homozygous β5t-G49S variation is not lethal. Both of  these 2 homozygotes 
experienced either hepatitis B or hepatitis C, even though the small number of  homozygotes hampers the 
statistically valid analysis of  the susceptibility of  homozygotes to individual diseases.
Cohort study identifies 5 individuals homozygous in β5t-G49S variation. We finally examined the β5t-
G49S variation in a cohort of  people in Nagahama City, Japan (21, 22). Among 9,730 participants 
of  the age range between 30 and 74 years old, 559 were heterozygous and 5 were homozygous in the 
β5t-G49S variation (Table 5). The minor allele frequency was 2.92%, similar to the frequencies in Jap-
anese populations in Tokyo and Tokushima (Supplemental Table 2 and Supplemental Table 3). The 
presence of  5 homozygotes in the 9,730 volunteers (at 0.051% = 2.3%2 frequency) indicated that the 
β5t-G49S variation in humans is neither lethal nor severely excluded in the population. The frequency 
and cellularity of  peripheral blood CD4+ T cells and CD8+ T cells, including naive CD8+ T cells, were 
not significantly different between the major allele homozygotes (209 samples) and the minor allele 
heterozygotes (12 samples) (Figure 6A), indicating that CD4+ and CD8+ T cells are not reduced in 
cellularity in the heterozygotes. So far, the data on CD8+ T cells are not available for the minor allele 
homozygotes. Nonetheless, as far as we are aware of, neither the heterozygotes nor the homozygotes 
were significantly associated with any severe diseases, including hepatitis B, hepatitis C, tuberculosis, 
and cancer (Figure 6B). Furthermore, we did not observe any increases in the frequency of  empyema, 
periodontitis, or asthmas (Figure 6B). The questionnaire survey did not reveal any significant problems 
in cold, cold-associated coughs, or sputum without cold among the heterozygotes or the homozygotes 
(Figure 6C), although the baseline survey detected a significant increase in coughs after colds in the 
homozygotes (Figure 6C). Thus, no severe health problems were noted in the heterozygous and homo-
zygous β5t-G49S variation detectable in the human cohort.
Table 3. Susceptibility to hepatitis B and hepatitis C in humans carrying β5t-G49S variation
Cases
Genotype Controls Hepatitis B Hepatitis C Spontaneous clearance of 
hepatitis C
Number  
(n = 417)
Frequency  
(%)
Number  
(n = 521)
Frequency     
(%)
Number  
(n = 2,537)
Frequency  
(%)
Number  
(n = 785)
Frequency  
(%)
G/G 393 94.24 491 94.24 2,405 94.80 741 94.39
G/A 24 5.76 29 5.57 132 5.20 43 5.48
A/A 0 0 1 0.19 0 0 1 0.13
Major G allele 810 97.12 1,011 97.03 4,942 97.40 1,525 97.13
Minor A allele 24 2.88 31 2.98 132 2.60 45 2.87
Genotype, number, and allele frequency in 521 hepatitis B patients, 2,537 hepatitis C patients, 785 individuals who underwent spontaneous clearance of 
hepatitis C virus, and 417 healthy controls in Japan are shown. Statistical analyses performed by Fisher’s exact test indicate no significant difference in 
minor allele frequency. The observed genotype distribution showed no significant deviation from the Hardy-Weinberg equilibrium (hepatitis B patients, 
χ2 = 0.67, degrees of freedom [df] = 1, P = 0.41; hepatitis C patients, χ2 = 0.81, df = 1, P = 0.18; individuals who underwent spontaneous clearance of 
hepatitis C, χ2 = 0.21, df = 1, P = 0.65; controls, χ2 = 0.37, df = 1, P = 0.55).
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Discussion
The rs34457782 single nucleotide variant, which is present at an appreciable frequency in human populations, 
changes the 49th amino acid of  β5t protein, Gly, to Ser (G49S). Our results indicate that human β5t protein 
with the G49S variation is inefficient and aberrant in the processing of  the propeptide to generate the mature 
β5t subunit that exposes the catalytically active triple threonine amino terminus. Unlike WT β5t protein, an 
appreciable fraction of  β5t-G49S protein incorporated in fully assembled proteasome complex either remains 
unprocessed or undergoes abnormal processing. The Gly at the 49th amino acid is highly conserved among 
vertebrate species, including humans and mice, and the processing of  mouse β5t-G49S protein is also ineffi-
cient and aberrant, similarly to the processing of  human β5t-G49S protein. By producing knock-in mice, we 
showed that the G49S variation in the mouse decreased β5t expression in cTECs in heterozygotes and homo-
zygotes, with the decrease being greater in the latter. The reduction of  β5t protein in cTECs might be due to 
the instability and/or the toxicity of  β5t-G49S–containing proteasome complex in the cells. The production 
of  CD8+ T cells was significantly impaired in homozygous, but not heterozygous, β5t-G49S–knock-in mice. 
These results indicate that the G49S variation in the genome affects the expression of  β5t-containing thymo-
proteasomes in cTECs and the thymic production of  CD8+ T cells in vivo, at least in mice.
However, no apparent health problems, including the susceptibility to hepatitis B virus, hepatitis C virus, 
or Mycobacterium tuberculosis, were detected in humans heterozygous in the rs34457782 variant, which may 
not be surprising, given the detection of no apparent problems in the immune cells, including the unreduced 
cellularity of CD8+ T cells, in the heterozygous β5t-G49S–knock-in mice. A publicly available database from 
Figure 5. Less severe reduction in β5t expression and CD8+ T cells in β5t-G49S–knock-in mice than β5t-deficient 
mice. (A) Relative fluorescence intensity (RFI, means ± SEM, n = 3) of β5t expression in cTECs from 2-week-old β5t-
G49S homozygous–knock-in mice (homo) and β5t-deficient mice (KO), normalized to the mean fluorescence intensity 
measured in WT cTECs. (B and C) Frequency (means ± SEM, n = 3) of CD4–CD8+ cells in TCRβhi cells of thymocytes (B) 
and splenocytes (C) in 6-week-old WT mice, β5t-G49S homozygous–knock-in mice (homo), and β5t-deficient mice 
(KO). *P < 0.05, **P < 0.01, ***P < 0.001 by one-way ANOVA with Tukey’s correction.
Table 4. Susceptibility to tuberculosis in humans carrying β5t-G49S variation
Cases
Genotype
Controls Tuberculosis
Number (n = 514) Frequency (%) Number (n = 573) Frequency (%)
G/G 505 98.25 567 98.95
G/A 9 1.75 6 1.05
A/A 0 0 0 0
Major G allele 1,019 99.12 1,140 99.48
Minor A allele 9 0.88 6 0.52
Genotype, number, and allele frequency in 573 tuberculosis patients and 514 healthy controls in Indonesia are shown. 
Statistical analyses performed by Fisher’s exact test indicate no significant difference in minor allele frequency. The 
observed genotype distribution showed no significant deviation from the Hardy-Weinberg equilibrium (tuberculosis 
patients, χ2 = 0.02, degrees of freedom [df] = 1, P = 0.90; controls, χ2 = 0.04, df = 1, P = 0.84).
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genome-wide association studies has revealed no apparent association of the β5t-G49S variation with any dis-
eases so far examined (DisGeNET v4.0, http://www.disgenet.org/web/DisGeNET/menu/search). Indeed, 
we found that the number of CD8+ T cells in heterozygous humans was not reduced. Nonetheless, the sig-
nificant reduction in β5t expression in cTECs (approximately 80% of the amount in WT cTECs), which was 
detectable in heterozygous mice, might still affect TCR repertoire and T cell function in CD8+ T cells produced 
in heterozygous humans.
On the other hand, it was rather surprising to readily find no severe health problems or no apparent 
association with various diseases in the 5 people who were identified as minor allele homozygotes in the 
cohort study. At the moment, the data on their CD8+ T cells and other immune cells in those homozygotes 
are not available, although the data for homozygous β5t-G49S–knock-in mice indicate that the cellularity 
of  their CD8+ T cells is reduced to approximately 40% of  those in the major-allele homozygotes. Thus, it is 
speculated that those homozygous people may also show reduced production of  functionally optimal CD8+ 
T cells and that they may experience reduced immune responses where CD8+ T cells are essential.
Nevertheless, we would like to point out that the minor allele frequency of this variant is appreciable at 
2.92% in a cohort in Japan (9,730 volunteers examined). The frequency of the 5 homozygotes found in the 9,730 
volunteers (0.051%) suggests that the β5t-G49S variation has little or no negative impact on the human popula-
tions. It is important to point out that this frequency of the homozygotes is overwhelmingly larger than those of  
extremely rare variations (reported in less than 30 patients worldwide) known to affect MHC class I-dependent 
generation of CD8+ T cells in humans (23–25). Those rare variations include the mutations deficient in the pep-
tide transporter complex TAP and TAP-associated protein TAPASIN, in which patients often suffer from respi-
ratory tract infection and skin granulomatous lesions but sometimes exhibit no clinical problems (23–25). Based 
on the results of this study, we would like to propose a careful and long-term analysis of health status in those 
rs34457782 minor allele populations, particularly in homozygotes, that carry the β5t-G49S variant, in hopes of  
better understanding the role of the thymoproteasome-dependent positive selection of CD8+ T cells in humans.
Figure 6. Nagahama study for β5t-G49S variation in humans. (A) Graph shows the frequency (top) and number (bottom) of indicated cell populations 
in peripheral white blood cells among 209 major allele homozygotes (G/G) and 12 minor allele heterozygotes (G/A). (B and C) Questionnaire survey of 
anamnesis was carried out in 9,166 major allele homozygotes (G/G), 559 minor allele heterozygotes (G/A), and 5 minor allele homozygotes (A/A) at the 
baseline assessment. The follow-up survey was carried out in 7,788 major allele homozygotes (G/G), 466 minor allele heterozygotes (G/A), and 5 minor allele 
homozygotes (A/A). Shown are the ratio of volunteers who experienced indicated diseases (filled bars in B) and the ratio of volunteers who caught colds for 
the indicated times per year (top), who experienced coughs after a cold (middle), and who noticed sputum without catching a cold (bottom) in 2 consecutive 
surveys (C). Logistic regression analyses and Jonckheere-Terpstra tests for the trend test indicated no statistically significant differences among the groups.
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Methods
Public database analysis. Single nucleotide variants of  human β5t-encoding sequence are 
available in the Single Nucleotide Polymorphism database (https://www.ncbi.nlm.
nih.gov/snp/) hosted by the National Center for Biotechnology Information (NCBI, 
dbSNP Human Build 141). The G49S variation among various populations is available 
in the 1000 Genome database in the NCBI public website (https://www.ncbi.nlm.nih.
gov/variation/tools/1000genomes/). Possible disease association of  rs34457782 vari-
ant was analyzed using DisGeNET v4.0 (http://www.disgenet.org/web/DisGeNET/
menu/search).
Human genome analysis. We initially performed a pilot sequencing of  the β5t-encoding 
region in human genome samples obtained from 188 healthy volunteers collected at the 
University of  Tokushima (Supplemental Table 3). After detecting 13 heterozygotes in the 
rs34457782 variant, we then examined this the in 949 healthy volunteers collected at the 
University of  Tokushima (10, 11), by using TaqMan genotyping assay (Applied Biosyste-
ms) in accordance with the manufacturer’s instructions.
Human genome analysis. SNP genotyping was conducted by using the TaqMan geno-
typing assay (Applied Biosystems) in accordance with the manufacturer’s instructions 
(Table 3 and Table 4). We genotyped 521 Japanese patients with hepatitis B, 2,537 Jap-
anese patients with hepatitis C, and 785 Japanese individuals with hepatitis C virus 
clearance, as well as 417 healthy Japanese patients. We also genotyped 573 Indonesian patients with 
tuberculosis and 514 healthy Indonesians.
Human epidemiological analysis. We analyzed a dataset of  the Nagahama Prospective Cohort for Com-
prehensive Human Bioscience (the Nagahama Study) to examine possible associations between rs34457782 
and clinical phenotypes in a human population (Figure 6 and Table 5). The Nagahama Study participants 
were recruited from 2008–2010 from community residents of  Nagahama City, a suburban city of  approxi-
mately 125,000 inhabitants in Shiga Prefecture, which is located in central Japan. Individuals who fulfilled 
the following criteria were included in this cohort, aged between 30 and 74 years old, living independently 
in the community, and having no apparent physical impairment or dysfunction. Among a total of  9,769 
participants, 9,730 participants whose rs34457782 genotype was available were considered in this study.
Participants in the Nagahama cohort study were invited to a follow-up assessment 5 years after baseline 
evaluations, and 8,294 of  the original 9,769 individuals participated in the follow-up survey. A dataset of  
the 8,259 participants whose rs34458872 genotype and clinical data were available was analyzed for the 
follow-up measurements.
DNA was extracted from peripheral blood specimen by a conventional phenol chloroform method, 
and rs34457782 genotype was analyzed by TaqMan assay using a predesigned primers and probe set 
(C_2111454_20, Applied Biosystems).
Clinical parameters — including the history of  hepatitis B, hepatitis C, tuberculosis, any cancers, maxil-
lary empyema, periodontitis diseases, bronchial asthma, and pediatric asthma — were obtained at the baseline 
measurement using a questionnaire. Frequency of  a cold and related symptoms were asked by the following 
questions at both baseline and follow-up measurements: How many colds do you have per year? (times), Do 
you have a cough after a cold? (yes/no), and Do you bring up sputum when you do not have a cold? (yes/no).
Blood samples from the participants of  the follow-up assessment in October 2014 were collected into 
tubes containing EDTA-2Na anticoagulant. Whole blood samples (50 μl) was directly stained with fluo-
rescence-labeled antibodies and incubated at 4°C for 30 minutes. The antibodies used were Pacific Blue–
labeled anti-CD3 antibody (clone UCHT1), APC-labeled anti-CD4 antibody (clone RPA-T4), APC-labeled 
anti-CD8a antibody (clone RPA-T8), Brilliant Violet 421-labeled anti-CD45RA antibody (clone HI100), 
APC-Cy7–labeled anti-CD45RO antibody (clone UCHL1), and Brilliant Violet 605-labeled anti-CCR7 
antibody (clone G043H7) (antibodies from SONY). Mixtures of  whole blood and antibodies were incu-
bated with 1 ml of  RBC lysis buffer (SONY) at room temperature for 15 minutes. The samples were pre-
served at 4°C, and propidium iodide (PI) was added 1 minute before the analysis. Data were acquired 
using a SONY SP6800 Spectral Analyzer, and results were analyzed with FlowJo software. Naive CD8+ 
T cells were identified as CCR7+CD45RA+CD45RO–CD3+CD8+ cells in the blood samples. The numbers 
of  viable white blood cells, which were defined by PI– cells, were measured by a flow cytometry based on 
electrical resistivity method (Sysmex XE-2100).
Table 5. Nagahama study for β5t-G49S 
variation in humans
Genotype Number Frequency (%)
G/G 9,166 94.20
G/A 559 5.75
A/A 5 0.05
   
Major G allele 18,891 97.08
Minor A allele 569 2.92
Genomic DNA from 9,730 volunteers participating 
in the Nagahama study were genotyped. 
Genotype, number, and allele frequency are 
indicated. The observed genotype distribution 
showed no significant deviation from the Hardy-
Weinberg equilibrium (χ2 = 1.41, degrees of 
freedom [df] = 1, P = 0.24). 
1 1insight.jci.org   https://doi.org/10.1172/jci.insight.93664
R E S E A R C H  A R T I C L E
Western blot analysis. HEK293T cells (RIKEN Bioresource Center), MEFs (2), and Plat-E cells (26) were 
cultured in DMEM (Nacalai Tesque) supplemented with 10% FBS (Thermo Fischer Scientific), 100 units/
ml penicillin, and 100 μg/ml streptomycin (Nacalai Tesque) at 37°C with 5% CO2. Genes were transfected 
by the conventional calcium phosphate method. MEFs were isolated from β5i-deficient mice and immor-
talized by introducing SV40 large T antigen (27). To generate MEFs stably expressing mouse β5t, pMXs 
plasmids encoding Flag-tagged β5t WT or G49S were transfected into Plat-E cells to prepare retroviruses 
(26). β5i-deficient MEFs were infected with the retroviruses and selected with 4 μg/ml puromycin for β5t 
expression. To generate HEK293T cells stably expressing human β5t, HEK293T cells were transfected 
with a pIRES plasmid encoding 3× Flag-tagged β5t and selected with 4 μg/ml puromycin. To promote the 
formation of  thymoproteasomes, MEFs were stimulated with mouse IFN-γ (Peprotech) at 50 units/ml for 
96 hours. Antibodies against Flag-tag were purchased from Sigma-Aldrich. Other antibodies against prote-
asome subunits used in this study were described previously (2, 28).
Cells were lysed in ice-cold buffer containing 0.2% NP-40, 25 mM Tris-HCl (pH 7.5), 1 mM dith-
iothreitol, 2 mM ATP, and 5 mM MgCl2, and clarified by centrifugation at 20,000 g for 15 minutes at 
4°C. Glycerol gradient centrifugation was performed as described previously (29). The 26S fractions 
were determined by measuring the hydrolysis of  succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin 
(Peptide Institute) (29). For immunoprecipitation, anti–Flag M2 agarose (Sigma-Aldrich) or anti-α6 
antibodies bound to Protein G-Sepharose (GE Healthcare) were used. For Western blotting, samples 
were boiled with SDS sample buffer, separated by SDS-PAGE, and transferred to a polyvinylidene 
difluoride membrane. Membranes were incubated with Blocking One (Nacalai Tesque) with primary 
antibodies and then with secondary antibodies conjugated to horseradish peroxidase (Jackson Immu-
noResearch, dilution 1:20,000) and visualized by Western Lightning Plus-ECL (Perkin Elmer). Images 
were obtained with LAS 4000 (GE Healthcare).
Generation of  β5t-G49S–knock-in mice. C57BL/6 (B6) mice were obtained from SLC. β5t-deficient mice 
and CAG-Cre transgenic mice were described previously (2, 30, 31). The targeting vector was prepared 
by cloning β5t-containing genomic fragments amplified from B6 mouse genomic DNA into pCR-Blunt 
vector (Invitrogen). Point mutation at the 145th nucleotide (49th amino acid) of  the β5t sequence was 
introduced with a PrimeSTAR mutagenesis basal kit (Takara). The fragment with the mutated β5t-cod-
ing sequence was subcloned into a plasmid containing a PGK-Neo cassette. The linearized targeting vec-
tor was introduced into TT2 ES cells (32) with 2 gRNAs targeting the β5t locus and the px335 plasmid, 
which encodes CRISPR and Cas9 nickase (33). The 2 gRNAs also target 5′ and 3′ arms of  the targeting 
vector, and the target sequences are as follows; 5′ arm, ATGCGCGCAAGAGTCACCGA: 3′ arm, ATG-
GATGGAACCATGCGGGC. Targeted alleles were screened by genomic PCR analysis and Southern 
blot analysis. The primers used for genomic PCR analysis were 5′- GTGGATGTGAATGCTTACGC - 3′ 
and 5′- AGAGGTTCACTAGTACTGGC - 3′. Mutation was confirmed by genome sequencing of  ES 
cells. Mice are available to the scientific community (accession no. CDB1255K, http://www2.clst.riken.
jp/arg/mutant%20mice%20list.html). β5t-G49S–knock-in mice were crossed with CAG-Cre transgenic 
mice to remove PGK-Neo cassette. Genomic PCR for genotyping β5t-G49S–knock-in mice, in which 
PGK-Neo cassette was removed, was carried out by using primers as follows: 5′ - CATGCCACCCAC-
CGTGATGC - 3′ on β5t-coding region and 5′ - GTCAGTCTTAGGACTGGAG - 3′ on β5t 3′ untranslat-
ed region. Targeted allele and WT allele were detected at 540 bp and 1.3 kb in size, respectively.
Southern blotting. Genomic DNA extracted from the spleen was digested with XbaI, electrophoresed in 
1% agarose, and transferred to nylon membrane (Hybond-N+, GE Healthcare). The probe was labeled with 
a PCR DIG Probe Synthesis Kit (Roche Diagnostics), and hybridization was detected using anti–DIG-AP 
Fab fragment (Roche Diagnostics), CDP-STAR (Roche Diagnostics), and Light Capture II (Atto).
Mouse genome sequencing. Genome DNA was PCR amplified and sequenced by using a Big Dye Terminator 
V3.1 cycle sequencing kit (Applied Biosystems) and analyzed by Genetic Analyzer 3500 (Applied Biosystems).
Thymic section analysis. Frozen thymuses embedded in OCT compound (Sakura Finetek) were sliced 
into 5-μm–thick sections. Thymic sections stained with H&E were examined under a light microscope. For 
immunofluorescence analysis, the thymuses were fixed in 4% (g/vol) paraformaldehyde and embedded in 
OCT compound. Frozen thymuses were sliced into 5-μm–thick sections and stained with anti-β5t antibody 
and UEA-1, followed by Alexa Fluor 488– and Alexa Fluor 546–conjugated secondary reagents, respec-
tively, and with Alexa Fluor 660–conjugated anti-Aire antibody (eBioscience, clone 5H12). Images were 
analyzed with a TSC SP8 confocal laser-scanning microscope (Leica).
1 2insight.jci.org   https://doi.org/10.1172/jci.insight.93664
R E S E A R C H  A R T I C L E
Flow cytometric analysis and isolation of  thymic epithelial cells. For the analysis of  thymocytes and spleno-
cytes, cells were stained for the expression of  CD4 (BioLegend, clone RM4-5), CD5 (BioLegend, clone 
53-7.3), CD8 (eBioscience, clone 53-6.7), CD44 (eBioscience, clone IM7), CD122 (BioLegend, clone 
TM-β1), and TCRβ (BioLegend, clone H57-597). Multicolor flow cytometry and cell sorting were per-
formed on FACSAriaII (BD Biosciences, clone 5H4). For the analysis of  thymic epithelial cells, minced 
thymuses were digested with 1 unit/ml liberase (Roche Diagnostics) in the presence of  0.01% DNase I 
(Roche Diagnostics). Single-cell suspensions were stained for the expression of  CD326 (EpCAM, Bio-
Legend, clone G8.8), CD45 (eBioscience, clone 30-F11), CD249 (Ly51, eBioscience, clone 6C3), H-2Kb 
(BioLegend, clone AF6-88.5), and I-Ab (BioLegend, clone AF6-120.1), and for the reactivity with UEA-1 
(Vector Laboratories).
Statistics. Statistical comparison in the analysis of  mice was performed with one-way ANOVA. Fisher’s 
exact test in a 2-by-2 contingency table was used to examine the association between rs34457782 and each 
phenotype (Table 3 and Table 4). In the analysis of  the Nagahama cohort dataset, a logistic regression 
model was adopted for the association analysis between rs34457782 genotype and binomial values, while a 
Jonckheere-Terpstra test was used for the trend test between the genotype and frequency of  catching a cold 
in a year (Figure 6). Only P values less than 0.05 were considered significant.
Study approval. All mouse experiments were performed with consent from the Animal Experimentation 
Committee of  the University of  Tokushima (T28-58), the Institutional Animal Care and Use Committee of  
RIKEN Kobe Branch (AH13-03), and the Institutional Animal Care Committee of  the Graduate School of  
Pharmaceutical Sciences, the University of  Tokyo (approval no. M25-19).
Regarding the human genome analysis described in Supplemental Table 3, all study procedures were 
approved by the Ethics Committee for Human Genome and Gene Research of  the University of  Tokushi-
ma. Written informed consent was obtained from all participants prior to enrollment in the study.
Regarding the human association studies described in Table 3 and Table 4, all study protocols con-
formed to relevant ethical guidelines as reflected in the a priori approval by the ethics committee of  the 
Faculty of  Medicine, The University of  Tokyo, and by the ethics committees of  all participating universities 
and hospitals. Written informed consent was obtained from all patients participating in this study, and all 
samples were anonymized.
Regarding the human cohort studies described in Figure 6 and Table 5, all study procedures were 
approved by the ethics committee of  the Kyoto University Graduate School of  Medicine and by the Naga-
hama Municipal Review Board. Written informed consent was obtained from all participants.
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